HELP
Cybin D/B/A Helus Pharma
NasdaqGMUSDEQUITY
DELAYED
Last price
12.43
▼ 0.04 (0.34%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
12.55
Prev close
12.47
Day high
12.95
Day low
12.47
Volume
2.16M
Market cap
—
P/E (TTM)
—
52W range
3.76 – 12.95
Trailing performance
Returnvs SPY
1W
+5.00%
+6.4%
1M
+62.87%
+59.1%
3M
+173.70%
+170.6%
6M
+84.88%
+73.8%
YTD
+53.91%
+41.6%
1Y
+90.76%
+70.8%
3Y
+2.57%
-71.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on HELP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Cost of revenue | — | — | — | — | $0 | — |
| Gross profit | — | — | — | — | $0 | — |
| Research & development | $86.59M | $39.21M | $32.36M | $25.49M | — | +120.8% |
| Selling, general & admin | $56.00M | $63.91M | $46.47M | $26.03M | — | -12.4% |
| Total operating expense | $142.59M | $103.13M | $78.84M | $51.52M | — | +38.3% |
| Operating income | -$142.59M | -$103.13M | -$78.84M | -$51.52M | — | -38.3% |
| Net interest income | $2.18M | $5.99M | $619.00K | $603.00K | — | -63.6% |
| Pre-tax income | -$148.00M | -$81.59M | -$78.08M | -$47.49M | — | -81.4% |
| Net income | -$148.00M | -$81.61M | -$78.08M | -$47.49M | — | -81.4% |
| Net income to common | -$148.00M | -$81.61M | -$78.08M | -$47.49M | — | -81.4% |
| Basic EPS | -4.25 | -4.04 | -6.96 | -9.88 | — | -5.2% |
| Diluted EPS | -4.25 | -4.04 | -6.96 | -9.88 | — | -5.2% |
| EBIT | -$142.59M | -$103.13M | -$78.84M | -$51.52M | — | -38.3% |
| EBITDA | -$142.47M | -$102.78M | -$78.41M | -$51.27M | — | -38.6% |
| Basic shares | 34.80M | 20.22M | 8.30M | 4.88M | — | +72.1% |
| Diluted shares | 34.80M | 20.22M | 8.30M | 4.88M | — | +72.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Cash & short-term investments | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Accounts receivable | $5.03M | $4.09M | $4.48M | $3.05M | +22.8% |
| Total current assets | $184.52M | $115.45M | $218.54M | $23.18M | +59.8% |
| Property, plant & equipment | $195.00K | $98.00K | $547.00K | $450.00K | +99.0% |
| Goodwill & intangibles | $66.45M | $64.35M | $82.94M | $30.26M | +3.3% |
| Total assets | $251.17M | $179.90M | $302.02M | $53.90M | +39.6% |
| Total current liabilities | $19.38M | $14.90M | $10.10M | $5.66M | +30.0% |
| Total debt | — | $0 | $291.00K | — | — |
| Total liabilities | $19.38M | $14.90M | $10.10M | $5.66M | +30.0% |
| Retained earnings | -$389.54M | -$255.39M | -$226.23M | -$148.15M | -52.5% |
| Shareholder equity | $231.79M | $165.00M | $291.93M | $48.23M | +40.5% |
| Working capital | $165.15M | $100.55M | $208.44M | $17.52M | +64.2% |
| Net tangible assets | $165.34M | $100.65M | $208.99M | $17.97M | +64.3% |
| Shares issued | 51.63M | 21.61M | 20.00M | 5.15M | +138.9% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$148.00M | -$81.61M | -$78.08M | -$47.49M | -81.4% |
| Depreciation & amortisation | $120.00K | $348.00K | $424.00K | $251.00K | -65.5% |
| Stock-based compensation | $10.86M | $31.28M | $13.89M | $4.69M | -65.3% |
| Change in working capital | -$1.26M | -$6.82M | -$5.03M | -$1.44M | +81.6% |
| Operating cash flow | -$133.27M | -$72.33M | -$68.91M | -$47.43M | -84.3% |
| Capital expenditure | -$1.37M | -$1.40M | -$710.00K | -$3.31M | +1.6% |
| Investing cash flow | -$1.36M | -$1.40M | $6.92M | -$3.31M | +2.4% |
| Financing cash flow | $198.24M | $14.10M | $254.51M | $13.56M | +1,306.4% |
| Free cash flow | -$134.64M | -$73.72M | -$69.62M | -$50.74M | -82.6% |
| End cash position | $157.26M | $93.92M | $208.99M | $16.63M | +67.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $28.89M | $23.86M | $18.85M | $14.99M | $18.97M | — | +21.1% |
| Selling, general & admin | $18.97M | $17.35M | $10.04M | $9.63M | $14.30M | — | +9.3% |
| Total operating expense | $47.86M | $41.21M | $28.89M | $24.62M | $33.27M | — | +16.1% |
| Operating income | -$47.86M | -$41.21M | -$28.89M | -$24.62M | -$33.27M | — | -16.1% |
| Net interest income | $1.58M | $1.50M | $1.06M | -$1.96M | $1.44M | — | +5.1% |
| Pre-tax income | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | — | -10.1% |
| Net income | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | — | -10.1% |
| Net income to common | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | — | -10.1% |
| Basic EPS | — | -1.00 | -1.39 | -1.10 | — | -0.38 | — |
| Diluted EPS | — | -1.00 | -1.39 | -1.10 | — | -0.38 | — |
| EBIT | -$47.86M | -$41.21M | -$28.89M | -$24.62M | -$33.27M | — | -16.1% |
| EBITDA | -$47.83M | -$41.19M | -$28.86M | -$24.59M | -$33.21M | — | -16.1% |
| Basic shares | — | 42.52M | 24.21M | 22.40M | — | 20.00M | — |
| Diluted shares | — | 42.52M | 24.21M | 22.40M | — | 20.00M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $157.26M | $195.13M | $83.75M | $118.69M | $93.92M | — | -19.4% |
| Cash & short-term investments | $157.26M | $195.13M | $83.75M | $118.69M | $93.92M | — | -19.4% |
| Accounts receivable | $5.03M | $4.77M | $4.74M | $4.11M | $4.09M | — | +5.5% |
| Total current assets | $184.52M | $222.90M | $114.58M | $143.65M | $115.45M | — | -17.2% |
| Property, plant & equipment | $195.00K | $186.00K | $125.00K | $82.00K | $98.00K | — | +4.8% |
| Goodwill & intangibles | $66.45M | $67.03M | $66.54M | $67.08M | $64.35M | — | -0.9% |
| Total assets | $251.17M | $290.11M | $181.25M | $210.81M | $179.90M | — | -13.4% |
| Total current liabilities | $19.38M | $16.18M | $13.36M | $14.55M | $14.90M | — | +19.8% |
| Long-term debt | — | — | $28.89M | $44.50M | — | — | — |
| Total debt | — | — | $28.89M | $44.50M | $0 | $0 | — |
| Total liabilities | $19.38M | $16.18M | $42.25M | $59.05M | $14.90M | — | +19.8% |
| Retained earnings | -$389.54M | -$342.54M | -$299.87M | -$266.15M | -$255.39M | — | -13.7% |
| Shareholder equity | $231.79M | $273.93M | $139.00M | $151.76M | $165.00M | — | -15.4% |
| Working capital | $165.15M | $206.72M | $101.22M | $129.10M | $100.55M | — | -20.1% |
| Net tangible assets | $165.34M | $206.90M | $72.46M | $84.68M | $100.65M | — | -20.1% |
| Shares issued | 51.63M | 49.89M | 26.10M | 23.03M | 21.61M | — | +3.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$46.99M | -$42.67M | -$33.72M | -$24.61M | -$30.58M | -10.1% |
| Depreciation & amortisation | $31.00K | $22.00K | $29.00K | $38.00K | $62.00K | +40.9% |
| Stock-based compensation | $5.26M | $4.48M | $377.00K | $753.00K | $2.09M | +17.4% |
| Change in working capital | $3.70M | $5.88M | -$7.06M | -$3.77M | $8.56M | -37.0% |
| Operating cash flow | -$37.29M | -$31.95M | -$34.48M | -$29.55M | -$21.11M | -16.7% |
| Capital expenditure | -$323.00K | -$383.00K | -$436.00K | -$231.00K | -$1.08M | +15.7% |
| Investing cash flow | -$323.00K | -$383.00K | -$436.00K | -$221.00K | -$1.08M | +15.7% |
| Financing cash flow | -$169.00K | $143.75M | $27.00K | $54.63M | $20.98M | -100.1% |
| Free cash flow | -$37.61M | -$32.33M | -$34.92M | -$29.78M | -$22.20M | -16.3% |
| End cash position | $157.26M | $195.13M | $83.75M | $118.69M | $135.02M | -19.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.51
+7.97% from price
SMA 20
10.24
+22.91% from price
SMA 50
7.77
+62.03% from price
SMA 100
6.36
+95.27% from price
SMA 200
6.43
+95.81% from price
EMA 12
11.33
+9.69% from price
EMA 26
9.97
+24.61% from price
EMA 50
8.54
+45.59% from price
RSI (14)
74.0
Overbought
MACD (12,26,9)
1.36
Hist 0.10
ATR (14)
0.88
7.03% of price
Realised vol 30D
94.7%
Annualised
Bollinger upper
13.72
20, 2σ
Bollinger lower
6.77
20, 2σ
50 / 200 cross
Golden
7.77 vs 6.43
Trend bias
Above 200
+95.81%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.17
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
94.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-55.6%
Peak to trough
Max drawdown 5Y
-96.4%
Peak to trough
ATR 14
0.88
7.03% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions
Simply Wall St. · 16h ago
3 Revenue Generating Psychedelics Stocks Retail Investors Are Screening Right Now
Simply Wall St. · 2d ago
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
GlobeNewswire · 5d ago
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
GlobeNewswire · 9d ago
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003
MarketBeat · 9d ago
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
GlobeNewswire · 12d ago
Cybin (HELP) Names New CEO, Is The Stock Still Cheap?
Simply Wall St. · 14d ago
Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed?
Simply Wall St. · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.